MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-13-2025
Milestone Scientific Cost of Revenue 2011-2025 | MLSS
Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.What is included in the cost of revenue
| Cost Category | Examples |
|---|---|
| Production Costs | Materials, wages of production staff, depreciation of equipment |
| Service and Support | Customer service, user support, technical assistance |
| Delivery and Logistics | Packaging, delivery of goods to customers |
| Hosting and Infrastructure | Servers, cloud platforms (especially for IT and SaaS companies) |
| Content and Licenses | License purchases, production royalties (e.g., in streaming services) |
Importance of the Metric
- Helps to understand how costly the revenue-generating process is.
- A high cost of revenue may indicate:
Poor cost control
Low operational efficiency - A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.
Annual Cost of Revenue Milestone Scientific
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.2 M | 3.03 M | 3.91 M | 3.99 M | 1.82 M | 2.66 M | 5.19 M | 4.31 M | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 5.19 M | 1.82 M | 3.39 M |
Quarterly Cost of Revenue Milestone Scientific
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 719 K | 706 K | 585 K | - | 678 K | 443 K | 573 K | - | 556 K | 1.02 M | 708 K | - | 763 K | 968 K | 1.02 M | - | 748 K | 1.06 M | 1.12 M | - | 410 K | 55.6 K | 527 K | - | 524 K | 752 K | 619 K | - | 1.74 M | 1.02 M | 563 K | - | 1.04 M | 874 K | 1.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.74 M | 55.6 K | 785 K |
Cost of Revenue of other stocks in the Medical instruments industry
| Issuer | Cost of Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Baxter International
BAX
|
6.65 B | $ 18.99 | 0.48 % | $ 9.68 B |  USA |
 |
Becton, Dickinson and Company
BDX
|
11.9 B | $ 200.87 | 0.22 % | $ 57.8 B | USA |
 |
BioLife Solutions
BLFS
|
8.76 M | $ 24.43 | -1.81 % | $ 1.13 B | USA |
 |
Ekso Bionics Holdings
EKSO
|
8.41 M | $ 4.79 | 2.35 % | $ 96.6 M | USA |
 |
DENTSPLY SIRONA
XRAY
|
1.84 B | $ 11.59 | -0.13 % | $ 2.36 B | USA |
 |
Alcon
ALC
|
3.58 B | $ 78.74 | -0.03 % | $ 40.4 B |  Schweiz |
 |
iRhythm Technologies
IRTC
|
184 M | $ 170.09 | 0.58 % | $ 5.31 B | USA |
 |
AtriCure
ATRC
|
118 M | $ 42.08 | 1.62 % | $ 1.98 B | USA |
 |
Atrion Corporation
ATRI
|
107 K | - | - | $ 810 M | USA |
 |
electroCore
ECOR
|
2.8 M | $ 4.81 | -0.21 % | $ 26.5 K | USA |
 |
Harvard Bioscience
HBIO
|
46.2 M | $ 0.76 | 1.78 % | $ 32.2 M | USA |
 |
AngioDynamics
ANGO
|
135 M | $ 13.12 | -2.42 % | $ 536 M | USA |
 |
The Cooper Companies
COO
|
1.41 B | $ 81.82 | -0.36 % | $ 16.3 B | USA |
 |
ICU Medical
ICUI
|
1.56 B | $ 147.72 | 0.34 % | $ 3.6 B | USA |
 |
Glaukos Corporation
GKOS
|
75.6 M | $ 109.57 | 0.31 % | $ 5.31 B | USA |
 |
Haemonetics Corporation
HAE
|
612 M | $ 83.2 | -1.49 % | $ 4.19 B | USA |
 |
InfuSystem Holdings
INFU
|
47.3 M | $ 9.24 | 0.33 % | $ 191 M | USA |
 |
Isoray
ISR
|
3.13 M | - | 0.03 % | $ 108 M | USA |
 |
Repro Med Systems
KRMD
|
11.8 M | $ 5.75 | -1.88 % | $ 262 M | USA |
 |
LeMaitre Vascular
LMAT
|
69 M | $ 83.51 | 0.18 % | $ 1.87 B | USA |
 |
Intuitive Surgical
ISRG
|
2.72 B | $ 541.3 | -1.11 % | $ 192 B | USA |
 |
Masimo Corporation
MASI
|
1.09 B | $ 138.1 | -2.25 % | $ 7.36 B | USA |
 |
Merit Medical Systems
MMSI
|
713 M | $ 86.52 | -0.01 % | $ 5.04 B | USA |
 |
Microbot Medical
MBOT
|
1.91 M | $ 2.43 | 2.21 % | $ 24.8 M |  Israel |
 |
Nephros
NEPH
|
5.83 M | $ 5.08 | 2.24 % | $ 52.8 M | USA |
 |
NeuroMetrix
NURO
|
1.35 M | - | 5.05 % | $ 9.02 M | USA |
 |
ResMed
RMD
|
1.55 B | $ 250.7 | -0.67 % | $ 36.6 B | USA |
 |
Envista Holdings Corporation
NVST
|
1.14 B | $ 21.79 | -1.58 % | $ 3.75 B | USA |
 |
OraSure Technologies
OSUR
|
106 M | $ 2.52 | -2.14 % | $ 188 M | USA |
 |
Pro-Dex
PDEX
|
47.1 M | $ 43.83 | 0.6 % | $ 144 M | USA |
 |
Pulse Biosciences
PLSE
|
11.9 M | $ 14.26 | 3.71 % | $ 685 M | USA |
 |
Predictive Oncology
POAI
|
826 K | $ 5.95 | 0.51 % | $ 32.4 M | USA |
 |
Repligen Corporation
RGEN
|
354 M | $ 156.65 | -3.1 % | $ 8.73 M | USA |
 |
Retractable Technologies
RVP
|
34.1 M | $ 0.83 | -0.31 % | $ 24.8 M | USA |
 |
STAAR Surgical Company
STAA
|
74.3 M | $ 24.16 | -2.11 % | $ 1.19 B | USA |
 |
STERIS plc
STE
|
3.06 B | $ 251.01 | -0.59 % | $ 24.7 B | USA |
 |
Stereotaxis
STXS
|
11.9 M | $ 2.38 | -1.45 % | $ 192 M | USA |
 |
Teleflex Incorporated
TFX
|
1.34 B | $ 125.81 | -1.13 % | $ 5.89 B | USA |
 |
Utah Medical Products
UTMD
|
20.2 M | $ 57.99 | 0.5 % | $ 210 M | USA |
 |
West Pharmaceutical Services
WST
|
1.89 B | $ 266.92 | -2.06 % | $ 19.5 B | USA |